## COVCOG 1: Factors predicting Cognitive Symptoms in Long COVID. A First Publication from the COVID and Cognition Study.

Panyuan Guo\*, Alvaro Benito Ballesteros\*, Sabine P Yeung\*, Ruby Liu\*, Arka Saha\*, Lyn Curtis°,

Muzaffer Kaser¥, Mark P Haggard\*, Lucy G Cheke\*1

Supplementary Materials

**Supplementary Table 1.** Distribution of profession and employment status before the pandemic in No COVID and COVID groups. Note that participants could choose multiple options.

	No COVID	COVID	
	(n = 185)	(n = 181)	Chi-square tests
Profession			
Not in paid work	66 (35.7%)	22 (12.2%)	$\chi^2(1) = 27.72, p < .001,$ $V = .275*$
Healthcare setting	16 (8.6%)	40 (22.1%)	$\chi^2(1) = 12.77, p < .001,$ $V = .187*$
Professional / Consultant / Academic	26 (14.1%)	29 (16%)	n.s.
Office Support / Administrative Work	17 (9.2%)	24 (13.3%)	n.s.
Education (Teaching / Childcare)	7 (3.8%)	19 (10.5%)	$\chi^2(1) = 6.25, p = .012,$ $V = .131$
Sales / Service	13 (7%)	8 (4.4%)	n.s.
Technician / Engineer / Mechanic	2 (1.1%)	7 (3.9%)	n.s.
Cleaner / Canteen Staff / Handyman	7 (3.8%)	1 (0.6%)	n.s.

Musician / Actor / Dancer and related	3 (1.6%)	3 (1.7%)	n.s.
performance work			
Construction / Agricultural / Forestry /	5 (2.7%)	1 (0.6%)	n.s.
Fishery worker			
Transport worker	4 (2.2%)	2 (1.1%)	n.s.
Craft / Art and related trade work	3 (1.6%)	1 (0.6%)	n.s.
Managerial	1 (0.5%)	1 (0.6%)	n.s.
Professional sports	-	1 (0.6%)	n.s.
Other	16 (14.1%)	25 (13.8%)	n.s.
ployment status before pandemic			
Full time	61 (33%)	103 (56.9%)	$\chi^2(1) = 21.19, p < .001,$
			V = .241*
Part time	39 (21.1%)	39 (21.5%)	n.s.
Part time in multiple jobs	6 (3.2%)	6 (3.3%)	n.s.
Other schedule (e.g., ad hoc / gig	3 (1.6%)	7 (3.9%)	n.s.
economy)			
Not working (unemployed / career	42 (22.7%)	16 (8.8%)	$\chi^2(1) = 13.18, p < .001,$
break / retired)			V = .190*
Unpaid carer (e.g., children / elders)	7 (3.8%)	7 (3.9%)	n.s.
Student (e.g., University)	50 (27%)	26 (14.4%)	$\chi^2(1) = 8.91, p = .003,$

<sup>\*</sup> denotes *p* values below Sidak-correct alpha (i.e. non-null)

Supplementary Table 2. Distribution of medical history in No COVID and COVID groups (top).

Descriptive statistics and analyses for health behaviours factors (1 = Never - 6 = Several times daily; higher scores indicating higher frequency) in No COVID and COVID groups (bottom).

No COVID

COVID

	NO COVID	COVID	
	(n = 185)	(n = 181)	
Medical history: Frequency (%)			Chi-square tests
Asthma	35 (18.9%)	38 (21%)	n.s.
Depression	38 (20.5%)	34 (18.8%)	n.s.
Other mental health disorder	35 (18.9%)	28 (15.5%)	n.s.
Obesity	15 (8.1%)	23 (12.7%)	n.s.
High blood pressure	20 (10.8%)	19 (10.5%)	n.s.
History of migraines	7 (3.8%)	19 (10.5%)	$\chi^2(1) = 6.25, p = .012,$
			V = .131
Inflammatory / Autoimmune	4 (2.2%)	18 (9.9%)	$\chi^2(1) = 9.81, p = .002,$
			V = .164*
Chronic fatigue syndrome /	9 (4.9%)	8 (4.4%)	n.s.
Myalgic encephalomyelitis (ME)			
Psychiatric/neurodevelopmental	6 (3.2%)	7 (3.9%)	n.s.
disorder			
Cardiovascular disease / Angina	4 (2.2%)	6 (3.3%)	n.s.
Diabetes (Type 2)	9 (4.9%)	2 (1.1%)	n.s.
Diabetes (Type 1)	4 (2.2%)	-	n.s.
Cancer	1 (0.5%)	2 (1.1%)	n.s.
A clotting disorder	1 (0.5%)	2 (1.1%)	n.s.

None of the above	79 (42.7%)	65 (35.9%)	n.s.
Health behaviours: <i>Mean (SD)</i>			Mann-Whitney U tests
Diet: Fruit and vegetables	4.66 (1.16)	5.04 (1.1)	COVID > No COVID:
			U = 13525, p = .001*
Diet: Sugary food	3.69 (1.11)	3.4 (1.07)	No COVID > COVID:
			U = 14168, p = .008*
Diet: Fatty food	3.26 (1.01)	3.06 (.86)	No COVID > COVID:
			U = 14825, p = .041
Physical activity	3.3 (1.24)	3.7 (1.33)	COVID > No COVID:
			U = 13752, p = .002*
Alcohol	2.67 (1.23)	2.69 (1.02)	n.s.
Smoking	1.63 (1.54)	1.4 (1.19)	n.s.

<sup>\*</sup> denotes p values below Sidak-correct alpha

**Supplementary Table 3.** Distribution of demographics in COVID subgroups: Recovered (*R*), Ongoing (Mild/Moderate (*C+*)) and Ongoing (Severe (*C++*)).

	Recovered	Ongoing	Ongoing	
	(R)	(Mild/Moderate)	(Severe)	
	(n = 42)	(C+)	(C++)	
		(n = 53)	(n = 66)	Chi-square tests
Weeks since infection				
3–10	15 (35.7%)	7 (13.2%)	4 (6.1%)	$\chi^2(6) = 19.64, p = .003,$
11–20	1 (2.4%)	4 (7.5%)	5 (7.6%)	V = .247
21–30	12 (28.6%)	15 (28.3%)	17 (25.8%)	
31+	14 (33.3%)	27 (50.9%)	40 (60.6%)	
Sex				
Man	13 (31%)	16 (30.2%)	10 (15.2%)	n.s.
Woman	29 (69%)	36 (67.9%)	54 (81.8%)	
Other	-	1 (1.9%)	2 (3%)	
Age				
18-20	9 (21.4%)	2 (3.8%)	-	$\chi^2(10) = 53.41, p < .001,$
21-30	14 (33.3%)	8 (15.1%)	2 (3%)	V = .407
31-40	10 (23.8%)	11 (20.8%)	14 (21.2%)	
41-50	3 (7.1%)	14 (26.4%)	16 (24.2%)	
51-60	4 (9.5%)	9 (17%)	26 (39.4%)	
61 or above	2 (4.8%)	9 (17%)	8 (12.1%)	
Education				
GCSE/equiv or below	7 (16.7%)	4 (7.5%)	2 (3%)	

A le	vel/equiv	7 (16.7%)	4 (7.5%)	2 (3%)	
Atte	ended college (no degree)	7 (16.7%)	13 (24.5%)	8 (12.1%)	
/ Te	echnical training /				
Ass	oc. degree				$\chi^2(10) = 20.03, p = .029,$
Вас	helor's degree	8 (19%)	15 (28.3%)	26 (39.4%)	V = .249
Ma	ster's / Professional	11 (26.2%)	13 (24.5%)	24 (36.4%)	
deg	ree				
Doo	torate degree	2 (4.8%)	4 (7.5%)	4 (6.1%)	
Countr	у				
UK		23 (54.8%)	34 (64.2%)	61 (92.4%)	$\chi^2(4) = 24.24, p < .001,$
Nor	th America	10 (23.8%)	12 (22.6%)	5 (7.6%)	V = .274
Oth	er	9 (21.4%)	7 (13.2%)	-	
Ethnici	ty				
Nor	thern European	29 (69%)	48 (90.6%)	62 (93.9%)	$\chi^2(2) = 14.68, p = .001,$
					<i>V</i> = .302
Sou	thern European / Latinx	6 (14.3%)	5 (9.4%)	5 (7.5%)	n.s.
Afri	can / Afro-Caribbean	4 (9.5%)	1 (1.9%)	2 (3%)	n.s.
Asia	an	4 (9.6%)	3 (5.7%)	-	n.s.
Oth	er / Prefer not to say	3 (7.2%)	1 (1.9%)	1 (1.5%)	n.s.

**Supplementary Table 4.** Diagnoses during initial illness among those seeking medical attention (N = 109).

Diagnoses within initial illness period	Percentage of positive diagnosis (number)
Нурохіа	14.7% (16)
TIA (Transient ischemic attack)	0.9% (1)
Clotting / Blood clots	5.5% (6)
Encephalopathies	0.9% (1)
Aneurism	1.8% (2)
Inflammatory Syndrome	4.6% (5)
Encephalitis	1.8% (2)
Hematoma	0.9% (1)
Kidney failure	0.9% (1)
Encephalomyelitis	-
Respiratory arrest	-
Delirium	1.8% (2)
Cardiac arrest	1.8% (2)
Stroke	2.8% (3)
Shock	1.8% (2)

**Supplementary Table 5.** Descriptive statistics and analyses for initial symptom experience (recoded such that higher numbers indicate increased severity: 1 = *Not at all*, 3 = *Very severe*) in COVID subgroups: Recovered (*R*), Ongoing (Mild/Moderate (*C*+)) and Ongoing (Severe (*C*++)).

		Recovered	Ongoing	Ongoing	
		(R)	(Mild/Moderate)	(Severe)	
		(n = 42)	(C+)	(C++)	
			(n = 53)	(n = 66)	Kruskal-Wallis H tests
Ini	itial symptoms: <i>Mean (S</i>	D)			
	Fatigue	2.24 (.69)	2.58 (.57)	2.76 (.47)	<i>H</i> (2) = 18.45, <i>p</i> < .001*
	Muscle/body pains	1.81 (.67)	2.17 (.58)	2.44 (61)	<i>H</i> (2) = 22.63, <i>p</i> < .001*
	Breathing issues	1.62 (.73)	2.04 (.73)	2.44 (.7)	<i>H</i> (2) = 28.04, <i>p</i> < .001*
	Headache	2 (.73)	2.04 (.68)	2.35 (.71)	H(2) = 8.51, p = .014
	Brain fog	1.62 (.76)	2.17 (.7)	2.26 (.79)	H(2) = 17.67, p < .001*
	Chest pain/tightness	1.55 (.63)	2.13 (.65)	2.26 (.73)	H(2) = 25.22, p < .001*
	Limb weakness	1.43 (.59)	1.75 (.62)	2.17 (.65)	<i>H</i> (2) = 31.14, <i>p</i> < .001*
	Dizziness	1.79 (.72)	1.83 (.7)	2.15 (.69)	H(2) = 9.01, p = .011
	Drowsiness	1.88 (.74)	2.19 (.71)	2.14 (.72)	n.s.
	Cough	2.02 (.75)	1.77 (.75)	2.08 (.83)	n.s.
	Loss of appetite	1.74 (.70)	1.7 (.75)	2.03 (.78)	H(2) = 6.51, p = .039
	Fever	1.71 (.64)	1.7 (.77)	1.98 (.79)	n.s.
	Abdominal pain	1.36 (.53)	1.58 (.66)	1.91 (.78)	<i>H</i> (2) = 14.84, <i>p</i> = .001*
	Altered consciousness	1.43 (.63)	1.66 (.62)	1.91 (.72)	H(2) = 13.09, p = .001*
	Loss of smell/taste	1.79 (.87)	1.74 (.88)	1.88 (.85)	n.s.
	Sore throat	1.67 (.69)	1.75 (.65)	1.85 (.69)	n.s.

Nausea	1.38 (.58)	1.51 (.61)	1.85 (.69)	H(2) = 15.03, p = .001*
Confusion	1.33 (.61)	1.58 (.69)	1.83 (.74)	H(2) = 13.94, p = .001*
Eye-soreness	1.48 (.67)	1.6 (.63)	1.8 (.73)	H(2) = 6.25, p = .044
Diarrhea	1.5 (.67)	1.55 (.61)	1.76 (.77)	n.s.
Anxiety	1.62 (.7)	1.72 (.63)	1.68 (.71)	n.s.
Blurred vision	1.19 (.46)	1.32 (.55)	1.62 (.67)	<i>H</i> (2) = 15.45, <i>p</i> < .001*
Disorientation	1.17 (.38)	1.47 (.58)	1.48 (.66)	H(2) = 8.78, p = .012
Acid reflux	1.21 (.47)	1.32 (.55)	1.45 (.66)	n.s.
Visual disturbances	1.19 (.4)	1.19 (.44)	1.36 (.65)	n.s.
Rash	1.14 (.42)	1.36 (.59)	1.32 (.53)	n.s.
Speech difficulty	1.14 (.35)	1.26 (.45)	1.32 (.53)	n.s.
Numbness	1.05 (.22)	1.23 (.47)	1.3 (.53)	H(2) = 8.51, p = .014
Vomiting	1.17 (.44)	1.08 (.33)	1.23 (.46)	n.s.
Hallucinations	1.07 (.26)	1.08 (.27)	1.23 (.55)	n.s.
Foot sores	1.07 (.34)	1.11 (.32)	1.2 (.4)	n.s.
Itchy welts	1.14 (.42)	1.25 (.43)	1.17 (.41)	n.s.
Delirium	1.14 (.35)	1.11 (.42)	1.15 (.47)	n.s.

<sup>\*</sup> denotes p values below Sidak-correct alpha (i.e. non-null)

**Supplementary Table 6.** Descriptive statistics and analyses for initial symptom experience (recoded such that higher numbers indicate increased severity: 1 = *Not at all*, 3 = *Very severe*) in Unknown, Unconfirmed COVID, and Confirmed COVID groups.

	Unknown	Unconfirmed	Confirmed	
	( <i>n</i> = 55)	(n = 96)	(n = 65)	Kruskal-Wallis H tests
Initial symptoms: Mean (SL	D)			
Fatigue	1.84 (.79)	2.58 (.63)	2.54 (.56)	<i>H</i> (2) = 36.94, <i>p</i> < .001*
Muscle/body pains	1.58 (.63)	2.17 (.71)	2.22 (.6)	<i>H</i> (2) = 30.09, <i>p</i> < .001*
Loss of smell/taste	1.22 (.57)	1.63 (.77)	2.08 (.92)	H(2) = 30.92, p < .001*
Drowsiness	1.55 (.66)	2.11 (.72)	2.05 (.74)	<i>H</i> (2) = 22, <i>p</i> < .001*
Brain fog	1.42 (.63)	2.08 (.77)	2.03 (.83)	H(2) = 26.67, p < .001*
Headache	1.96 (.61)	2.25 (.68)	2.02 (.76)	<i>H</i> (2) = 7.63, <i>p</i> = .022
Breathing issues	1.51 (.66)	2.22 (.76)	1.91 (.81)	H(2) = 27.87, p < .001*
Dizziness	1.53 (.6)	2 (.7)	1.88 (.74)	<i>H</i> (2) = 15.78, <i>p</i> < .001*
Chest pain/tightness	1.4 (.56)	2.16 (.73)	1.85 (.71)	<i>H</i> (2) = 36.05, <i>p</i> < .001*
Fever	1.49 (.64)	1.8 (.73)	1.85 (.8)	<i>H</i> (2) = 7.96, <i>p</i> = .019
Loss of appetite	1.45 (.66)	1.86 (.73)	1.82 (.81)	<i>H</i> (2) = 11.72, <i>p</i> = .003
Limb weakness	1.29 (.5)	1.86 (.71)	1.8 (.67)	<i>H</i> (2) = 27.62, <i>p</i> < .001*
Cough	2.05 (.65)	2.09 (.78)	1.77 (.77)	<i>H</i> (2) = 7.77, <i>p</i> = .021
Altered consciousness	1.35 (.62)	1.73 (.7)	1.66 (.67)	<i>H</i> (2) = 13.15, <i>p</i> = .001*
Anxiety	1.84 (.76)	1.69 (.62)	1.66 (.76)	n.s.
Eye-soreness	1.38 (.56)	1.69 (.65)	1.6 (.75)	<i>H</i> (2) = 7.89, <i>p</i> = .019
Sore throat	2.02 (.62)	1.9 (.67)	1.58 (.64)	<i>H</i> (2) = 14.61, <i>p</i> = .001*
Diarrhea	1.36 (.49)	1.65 (.71)	1.58 (.68)	n.s.

Abdominal pain	1.4 (.6)	1.72 (.72)	1.57 (.71)	H(2) = 7.54, p = .023
Nausea	1.38 (.53)	1.67 (.66)	1.54 (.66)	H(2) = 6.78, p = .034
Confusion	1.25 (.52)	1.69 (.74)	1.52 (.67)	<i>H</i> (2) = 14.15, <i>p</i> = .001*
Acid reflux	1.22 (.46)	1.29 (.54)	1.43 (.64)	n.s.
Disorientation	1.18 (.43)	1.45 (.61)	1.32 (.53)	H(2) = 8.37, p = .015
Blurred vision	1.2 (.52)	1.5 (.62)	1.28 (.57)	H(2) = 15.03, p = .001*
Rash	1.18 (.51)	1.3 (.53)	1.26 (.54)	n.s.
Visual disturbances	1.13 (.34)	1.29 (.54)	1.22 (.52)	n.s.
Numbness	1.07 (.26)	1.23 (.47)	1.18 (.43)	n.s.
Speech difficulty	1.04 (.19)	1.3 (.51)	1.18 (.39)	H(2) = 13.76, p = .001*
Itchy welts	1.18 (.55)	1.21 (.43)	1.15 (.4)	n.s.
Foot sores	1.04 (.27)	1.15 (.38)	1.12 (.33)	n.s.
Vomiting	1.15 (.41)	1.19 (.44)	1.12 (.38)	n.s.

<sup>\*</sup> denotes p values below Sidak-correct alpha (i.e. non-null)

**Supplementary Table 7.** Descriptive statistics and analyses for ongoing symptom experience (recoded such that higher numbers indicate increased severity: 1 = *Not at all*, 5 = *Very severe and often*) in Unknown, Unconfirmed COVID, and Confirmed COVID groups.

	Unknown	Unconfirmed	Confirmed	
	(n = 31)	(n = 88)	(n = 58)	Kruskal-Wallis H tests
Ongoing symptoms: Mean (SD)				
Fatigue	2.55 (1.5)	3.77 (1.35)	3.83 (1.39)	<i>H</i> (2) = 16.86, <i>p</i> < .001*
Difficulty concentrating	2.03 (1.05)	3.64 (1.22)	3.52 (1.3)	<i>H</i> (2) = 32.58, <i>p</i> < .001*
Brain fog	1.97 (1.33)	3.43 (1.45)	3.24 (1.49)	H(2) = 20.73, p < .001*
Forgetfulness	2.35 (1.31)	3.27 (1.32)	3.19 (1.34)	H(2) = 10.92, p = .004
Tip of the Tongue (ToT)	1.65 (0.92)	3 (1.41)	3.16 (1.41)	<i>H</i> (2) = 25.71, <i>p</i> < .001*
Difficulty sleeping	2.35 (1.33)	3.15 (1.41)	2.86 (1.16)	H(2) = 8.09, p = .017
Muscle/body pains	1.71 (0.78)	2.83 (1.39)	2.83 (1.48)	<i>H</i> (2) = 16.32, <i>p</i> < .001*
Breathing issues	2 (1.29)	2.98 (1.47)	2.83 (1.4)	H(2) = 11.07, p = .004
Fast/irregular pulse	1.39 (0.88)	2.85 (1.41)	2.81 (1.5)	<i>H</i> (2) = 29.07, <i>p</i> < .001*
Semantic disfluency	1.35 (0.88)	2.64 (1.42)	2.78 (1.49)	<i>H</i> (2) = 26.08, <i>p</i> < .001*
Night waking	2.23 (1.33)	3.24 (1.38)	2.74 (1.33)	<i>H</i> (2) = 13.18, <i>p</i> = .001*
Chest pain/tightness	1.84 (1.21)	2.89 (1.44)	2.69 (1.26)	H(2) = 14.61, p = .001*
Vivid dreams	2.03 (1.3)	2.78 (1.15)	2.62 (1.32)	H(2) = 9.12, p = .01
Dizziness	1.9 (1.17)	2.67 (1.32)	2.57 (1.42)	H(2) = 8.33, p = .016
Drowsiness	2.06 (1.39)	2.35 (1.25)	2.53 (1.33)	n.s.
Headache	2.32 (1.05)	2.78 (1.33)	2.53 (1.31)	n.s.
Limb weakness	1.42 (0.67)	2.38 (1.34)	2.47 (1.47)	<i>H</i> (2) = 14.53, <i>p</i> < .001*
Depression	3.03 (1.33)	2.51 (1.3)	2.43 (1.24)	n.s.

Excess thirst	1.77 (1.12)	2.43 (1.35)	2.41 (1.36)	H(2) = 6.69, p = .035
Loss of smell/taste	1.16 (0.52)	1.84 (1.21)	2.38 (1.62)	<i>H</i> (2) = 16.25, <i>p</i> < .001*
Head pressure	1.68 (0.95)	2.4 (1.38)	2.31 (1.35)	H(2) = 6.53, p = .038
Anxiety	2.65 (1.52)	2.45 (1.33)	2.24 (1.26)	n.s.
Confusion	1.39 (0.67)	2.18 (1.3)	2.22 (1.36)	H(2) = 9.89, p = .007
Weight gain	1.81 (1.25)	2.1 (1.33)	2.16 (1.35)	n.s.
Abdominal pain	1.71 (1.07)	2.22 (1.16)	2 (1.14)	H(2) = 6.44, p = .04
Pins & needles	1.68 (1.01)	2.19 (1.26)	1.98 (1.16)	n.s.
Sore throat	1.94 (1.03)	2.33 (1.22)	1.93 (1.23)	H(2) = 6.38, p = .041
Loss of appetite	1.48 (0.57)	1.83 (1.08)	1.9 (1.28)	n.s.
Altered consciousness	1.65 (1.17)	1.85 (1.17)	1.9 (1.2)	n.s.
Diarrhea	1.52 (0.81)	1.91 (1.02)	1.9 (1.14)	n.s.
Acid reflux	1.39 (0.8)	1.68 (1.09)	1.88 (1.26)	n.s.
Eye-soreness	1.65 (1.08)	2.26 (1.19)	1.88 (1.31)	H(2) = 11.27, p = .004
Blurred vision	1.39 (0.76)	2.03 (1.24)	1.84 (1.27)	H(2) = 8.14, p = .017
Nausea	1.48 (0.85)	1.89 (0.95)	1.79 (1.21)	H(2) = 6.32, p = .042
Cough	2.16 (1.39)	2.31 (1.16)	1.79 (0.95)	H(2) = 7.12, p = .028
Hot flushes	1.26 (0.58)	1.84 (1.12)	1.74 (1.21)	H(2) = 7.88, p = .019
Weight loss	1.48 (0.89)	1.52 (0.99)	1.62 (1.09)	n.s.
Disorientation	1.29 (0.82)	1.57 (0.84)	1.48 (0.98)	n.s.
Visual disturbances	1.23 (0.62)	1.52 (0.98)	1.47 (0.98)	n.s.
Speech difficulty	1.19 (0.65)	1.66 (0.98)	1.43 (0.9)	H(2) = 9.45, p = .009
Numbness	1.23 (0.62)	1.6 (1.06)	1.43 (0.94)	n.s.
Rash	1.39 (0.96)	1.55 (1.04)	1.4 (0.79)	n.s.
Fever	1.13 (0.43)	1.42 (0.85)	1.33 (0.85)	n.s.

Incontinence	1.16 (0.58)	1.27 (0.6)	1.28 (0.7)	n.s.
Itchy welts	1.32 (0.91)	1.24 (0.66)	1.22 (0.53)	n.s.
Foot sores	1.06 (0.25)	1.22 (0.65)	1.17 (0.57)	n.s.
Vomiting	1.13 (0.43)	1.19 (0.48)	1.17 (0.53)	n.s.

<sup>\*</sup> denotes p values below Sidak-correct alpha (i.e. non-null)

## **Supplementary Table 8.** Factors and loadings from the "since then" cognitive symptoms PCA.

## **Cognitive Symptoms**

Brain Fog	0.889
Forgetfulness	0.881
Tip of the Tongue (ToT)	0.879
Semantic Disfluency	0.874
Difficulty Concentrating	0.859

**Supplementary Table 9.** Distribution of experience with long COVID in COVID subgroups: Recovered (R), Ongoing (Mild/Moderate (C+)) and Ongoing (Severe (C++)).

	Now	Ongoing	Ongoing	
	Recovered	(Mild/Moderate)	(Severe)	
	(R)	(C+)	(C++)	
	(n = 27**)	(n = 53)	( <i>n</i> = 66)	Chi-square tests
Identify as suffering from "Lon	g COVID"			
Yes	3 (11.1%)	43 (81.1%)	62 (93.9%)	$\chi^2(4) = 85.75, p < .001,$
No	16 (59.3%)	2 (3.8%)	-	V = .542
Other	8 (29.6%)	8 (15.1%)	4 (6.1%)	
Change of symptoms after init	ial illness			
No ongoing symptoms	5 (18.5%)	-	-	
after initial recovery				
Different symptoms at	8 (29.6%)	28 (52.8%)	39 (59.1%)	-
different times				$\chi^2(6) = 37.52, p < .001,$
Improvement in	5 (18.5%)	18 (34%)	9 (13.6%)	V = .367
symptoms over time				
Symptoms have been	3 (11.1%)	7 (13.2%)	17 (25.8%)	_
very consistent				
I don't know / N/A	6 (22.2%)	-	1 (1.5%)	_
Cycle of symptoms after initial	illness			
Cycle every few days	3 (11.1%)	11 (20.8%)	14 (21.2%)	
Cycle every few weeks	3 (11.1%)	13 (24.5%)	19 (28.8%)	
Cycle monthly	2 (7.4%)	7 (13.2%)	9 (13.6%)	n.s.

No cycling	12 (44.4%)	19 (35.8%)	23 (34.8%)	
N/A	7 (25.9%)	3 (5.7%)	1 (1.5%)	
Impacts of long COVID				
Long period unable to	2 (7.4%)	15 (28.3%)	50 (75.8%)	$\chi^2(2) = 46.42, p < .001,$
work (due to illness)				V = .564*
Difficulty coping day-to-	6 (22.2%)	28 (52.8%)	48 (72.7%)	$\chi^2(2) = 20.23, p < .001,$
day activities				V = .372*
Difficulty getting medical	1 (3.7%)	21 (39.6%)	38 (57.6%)	$\chi^2(2) = 23.05, p < .001,$
professionals to take				V = .397*
symptoms seriously				
Lost job due to illness	1 (3.7%)	9 (17%)	32 (48.5%)	$\chi^2(2) = 24.39, p < .001,$
				V = .409*
Feeling that you have				
reening that you have	4 (14.8%)	21 (39.6%)	31 (47%)	$\chi^2(2) = 8.44, p = .015,$
experienced a trauma	4 (14.8%)	21 (39.6%)	31 (47%)	$\chi^2(2) = 8.44, p = .015,$ $V = .240$
	1 (3.7%)	21 (39.6%) 7 (13.2%)	31 (47%)	
experienced a trauma				V = .240
experienced a trauma Financial difficulty (as a				V = .240

<sup>\*</sup> denotes p values below Sidak-correct alpha at .007 for the impacts of long COVID

<sup>\*\*</sup>Excluding a small portion of participants who reported asymptomatic or feeling completely better very quickly from the Recovered subgroup (n = 15)

**Supplementary Table 10.** Descriptive statistics and analyses for ongoing symptom experience (recoded such that higher numbers indicate increased severity: 1 = *Not at all*, 5 = *Very severe and often*) in COVID subgroups: Recovered (*R*), Ongoing (Mild/Moderate (*C*+)) and Ongoing (Severe (*C*++)).

	Now	Ongoing	Ongoing	
	Recovered	(Mild/Moderate)	(Severe)	
	(R)	(C+)	(C++)	
	(n = 27**)	(n = 53)	(n = 66)	Kruskal-Wallis H tests
Ongoing symptoms: Mean (	SD)			
Fatigue	2.33 (1.24)	3.57 (1.12)	4.58 (0.98)	<i>H</i> (2) = 57.34, <i>p</i> < .001*
Difficulty concentrating	2.33 (1.36)	3.26 (1)	4.36 (0.78)	<i>H</i> (2) = 52.98, <i>p</i> < .001*
Brain fog	1.85 (1.26)	3.17 (1.21)	4.12 (1.18)	<i>H</i> (2) = 46.08, <i>p</i> < .001*
Forgetfulness	2.07 (1.24)	2.98 (1.08)	3.92 (1.13)	H(2) = 39.24, p < .001*
Tip of the Tongue (ToT)	1.78 (1.16)	2.81 (1.18)	3.79 (1.23)	<i>H</i> (2) = 41.03, <i>p</i> < .001*
Breathing issues	1.63 (1.15)	2.57 (1.07)	3.73 (1.32)	<i>H</i> (2) = 46.08, <i>p</i> < .001*
Fast/irregular pulse	1.59 (0.8)	2.45 (1.25)	3.65 (1.31)	<i>H</i> (2) = 45.11, <i>p</i> < .001*
Night waking	2 (1.27)	2.87 (1.35)	3.61 (1.16)	H(2) = 27.25, p < .001*
Muscle/body pains	1.67 (0.83)	2.51 (1.15)	3.56 (1.41)	H(2) = 37.66, p < .001*
Chest pain/tightness	1.70 (1.03)	2.43 (1.14)	3.56 (1.24)	H(2) = 42.21, p < .001*
Semantic disfluency	1.59 (0.84)	2.19 (1.24)	3.55 (1.3)	<i>H</i> (2) = 45.81, <i>p</i> < .001*
Difficulty sleeping	2.67 (1.44)	2.81 (1.21)	3.36 (1.3)	H(2) = 7.47, p = .024
Headache	1.96 (1.19)	2.23 (1.03)	3.35 (1.3)	H(2) = 30.33, p < .001*
Dizziness	1.81 (1.18)	2.19 (1.04)	3.32 (1.33)	H(2) = 31.94, p < .001*
Limb weakness	1.22 (0.42)	2.13 (1.09)	3.12 (1.45)	H(2) = 40.54, p < .001*
Head pressure	1.67 (0.92)	1.94 (0.97)	2.98 (1.52)	<i>H</i> (2) = 22.01, <i>p</i> < .001*

Vivid dreams	2.07 (1.17)	2.79 (1.1)	2.92 (1.26)	H(2) = 9.94, p = .007
Excess thirst	1.74 (1.16)	2.23 (1.2)	2.86 (1.40)	H(2) = 15.74, p < .001*
Sore throat	1.33 (0.56)	1.91 (0.9)	2.73 (1.4)	H(2) = 26.45, p < .001*
Drowsiness	1.78 (1.01)	2.4 (1.28)	2.71 (1.3)	H(2) = 11.11, p = .004
Confusion	1.33 (0.83)	2.02 (1.01)	2.7 (1.49)	H(2) = 21.82, p < .001*
Pins & needles	1.41 (0.64)	1.75 (0.88)	2.68 (1.38)	H(2) = 24.69, p < .001*
Abdominal pain	1.44 (0.7)	1.81 (0.74)	2.67 (1.33)	<i>H</i> (2) = 25.12, <i>p</i> < .001*
Eye-soreness	1.48 (0.8)	1.94 (1.08)	2.5 (1.4)	H(2) = 13.46, p = .001*
Blurred vision	1.19 (0.56)	1.68 (0.98)	2.5 (1.41)	H(2) = 28.35, p < .001*
Cough	1.59 (0.84)	1.92 (1.04)	2.46 (1.16)	<i>H</i> (2) = 14.55, <i>p</i> = .001*
Anxiety	2.19 (1.3)	2.38 (1.35)	2.44 (1.28)	n.s.
Depression	2.48 (1.37)	2.55 (1.2)	2.42 (1.31)	n.s.
Weight gain	1.56 (0.75)	2.06 (1.17)	2.41 (1.56)	n.s.
Loss of smell/taste	1.63 (1.25)	1.89 (1.2)	2.36 (1.57)	H(2) = 6.27, p = .044
Nausea	1.22 (0.51)	1.62 (0.74)	2.29 (1.25)	<i>H</i> (2) = 22.88, <i>p</i> < .001*
Loss of appetite	1.59 (0.97)	1.51 (0.89)	2.23 (1.31)	H(2) = 14.11, p = .001*
Diarrhoea	1.44 (0.58)	1.77 (0.89)	2.2 (1.26)	H(2) = 8.28, p = .016
Altered consciousness	1.22 (0.51)	1.81 (1.13)	2.18 (1.3)	H(2) = 15.09, p = .001*
Hot flushes	1.33 (0.78)	1.68 (0.96)	2.09 (1.34)	H(2) = 8.66, p = .013
Acid reflux	1.33 (0.62)	1.68 (1.12)	2 (1.3)	n.s.
Speech difficulty	1.04 (0.19)	1.38 (0.63)	1.94 (1.19)	<i>H</i> (2) = 18.85, <i>p</i> < .001*
Numbness	1.11 (0.32)	1.36 (0.79)	1.85 (1.24)	H(2) = 11.93, p = .003
Visual disturbances	1.15 (0.46)	1.31 (0.7)	1.8 (1.22)	H(2) = 10.6, p = .005
Disorientation	1.07 (0.27)	1.47 (0.75)	1.77 (1.08)	H(2) = 11.79, p = .003
Rash	1.07 (0.27)	1.42 (0.93)	1.71 (1.08)	H(2) = 11.39, p = .003

Fever	1.15 (0.46)	1.15 (0.41)	1.67 (1.11)	H(2) = 11.63, p = .003
Weight loss	1.52 (1.05)	1.51 (0.95)	1.62 (1.09)	n.s.
Incontinence	1.22 (0.58)	1.25 (0.55)	1.32 (0.73)	n.s.
Itchy welts on skin	1.07 (0.27)	1.25 (0.62)	1.29 (0.7)	n.s.
Foot sores	1.07 (0.39)	1.15 (0.5)	1.29 (0.76)	n.s.
Vomiting	1.11 (0.42)	1.09 (0.35)	1.26 (0.62)	n.s.

<sup>\*</sup> denotes p values below Sidak-correct alpha (i.e. non-null)

<sup>\*\*</sup>Excluding a small portion of participants who reported asymptomatic or feeling completely better very quickly from the Recovered subgroup (n = 15)

## Analysis on Current symptoms

We examined symptoms reported as present or absent over the past 1–2 days (n = 124, see Supplementary Table 11). Twelve symptoms appeared in less than 10% participants so were not included in the analyses. Pearson's chi-square tests with Sidak correction adjusting the alpha level to .0013 showed that the COVID subgroups significantly differed in their current experience of semantic disfluency only, with the symptom appearing more commonly in the C++ (Severe) subgroup than the other subgroups.

**Supplementary Table 11.** Distribution of current symptoms in COVID subgroups: Recovered (R), Ongoing (Mild/Moderate (C+)) and Ongoing (Severe (C++)).

		Recovered	Ongoing	Ongoing	
		(R)	(Mild/Moderate)	(Severe)	
		(n = 8**)	(C+)	(C++)	
			( <i>n</i> = 50**)	( <i>n</i> = 66)	Chi-square tests
Cı	urrent symptoms: Frequen	cy (%)			
	Fatigue	5 (62.5%)	37 (74%)	57 (86.4%)	n.s.
	Difficulty concentrating	5 (62.5%)	36 (72%)	56 (84.8%)	n.s.
	Forgetfulness	3 (37.5%)	30 (60%)	52 (78.8%)	$\chi^2(2) = 8.48, p = .014,$
					V = .262
	Brain fog	2 (25%)	34 (68%)	50 (75.8%)	$\chi^2(2) = 8.72, p = .013,$
					V = .265
	Breathing issues	2 (25%)	24 (48%)	49 (74.2%)	$\chi^2(2) = 12.7, p = .002,$
					V = .32
	Tip of the Tongue (ToT)	1 (12.5%)	28 (56%)	46 (69.7%)	$\chi^2(2) = 10.47, p = .005,$
					V = .291

Night waking	5 (62.5%)	28 (56%)	43 (65.2%)	n.s.
Chest pain/tightness	1 (12.5%)	24 (48%)	43 (65.2%)	$\chi^2(2) = 9.57, p = .008,$
				V = .278
Muscle/body pains	2 (25%)	22 (44%)	43 (65.2%)	$\chi^2(2) = 8.03, p = .018,$
				V = .254
Headache	2 (25%)	20 (40%)	40 (60.6%)	$\chi^2(2) = 6.97, p = .031,$
				V = .237
Semantic disfluency	1 (12.5%)	13 (26%)	40 (60.6%)	$\chi^2(2) = 17.21, p < .001,$
				V = .373*
Dizziness	4 (50%)	14 (28%)	38 (57.6%)	$\chi^2(2) = 10.13, p = .006,$
				V = .286
Fast/irregular pulse	2 (25%)	17 (34%)	35 (53%)	n.s.
Difficulty sleeping	5 (62.5%)	19 (38%)	32 (48.5%)	n.s.
Head pressure	1 (12.5%)	15 (30%)	32 (48.5%)	$\chi^2(2) = 6.57, p = .037,$
				V = .23
Sore throat	-	14 (28%)	28 (42.4%)	$\chi^2(2) = 7.02, p = .03,$
				V = .238
Eye-soreness	2 (25%)	15 (30%)	27 (40.9%)	n.s.
Limb weakness	1 (12.5%)	16 (32%)	27 (40.9%)	n.s.
Anxiety	3 (37.5%)	19 (38%)	25 (37.9%)	n.s.
Blurred vision	1 (12.5%)	7 (14%)	25 (37.9%)	$\chi^2(2) = 9.18, p = .01,$
				V = .272
Vivid dreams	2 (25%)	18 (36%)	24 (36.4%)	n.s.
Depression	4 (50%)	22 (44%)	23 (34.8%)	n.s.
Weight gain	2 (25%)	13 (26%)	22 (33.3%)	n.s.

Pins & needles	2 (25%)	9 (18%)	22 (33.3%)	n.s.
Cough	2 (25%)	15 (30%)	21 (31.8%)	n.s.
Abdominal pain	-	9 (18%)	21 (31.8%)	n.s.
Loss of smell/taste	1 (12.5%)	14 (28%)	19 (28.8%)	n.s.
Confusion	2 (25%)	9 (18%)	19 (28.8%)	n.s.
Excess thirst	6 (75%)	17 (34%)	18 (27.3%)	$\chi^2(2) = 7.38, p = .025,$
				V = .244
Hot flushes	2 (25%)	6 (12%)	18 (27.3%)	n.s.
Drowsiness	2 (25%)	14 (28%)	18 (27.3%)	n.s.
Nausea	-	8 (16%)	16 (24.2%)	n.s.
Loss of appetite	-	7 (14%)	13 (19.7%)	n.s.
Speech difficulty	-	1 (2%)	13 (19.7%)	$\chi^2(2) = 9.98, p = .007,$
				V = .284
Diarrhoea	1 (12.5%)	11 (22%)	13 (19.7%)	n.s.
Altered consciousness	-	7 (14%)	12 (18.2%)	n.s.
Acid reflux	-	8 (16%)	12 (18.2%)	n.s.
Numbness	-	3 (6%)	11 (16.7%)	n.s.
Weight loss	1 (12.5%)	7 (14%)	9 (13.6%)	n.s.
Visual disturbances	-	4 (8%)	9 (13.6%)	n.s.

<sup>\*</sup> denotes p values below Sidak-correct alpha (i.e. non-null)

<sup>\*\*</sup>Further excluding a small portion of participants who reported asymptomatic or feeling completely better very quickly from the Recovered subgroup (n = 15) and an additional group of participants who reported not experiencing current symptoms (n = 22)

**Supplementary Table 12.** Factor loadings for current symptoms (binary present/absent data).

Symptom		Comp	onent	
	1	2	3	4
Breathing issues	0.647			
Chest pain/tightness	0.593			
Fatigue	0.557	0.302		
Weight gain	0.534			
Cough	0.533			
Muscle/body pains	0.513	0.3		
Sore throat	0.508			
Night waking	0.488		0.337	
Vivid dreams	0.386			
Excess thirst	0.368			
Fever	0.352			
Loss of smell/taste	0.294			
Rash	0.254			
Vomiting	0.263			
Hot flushes		0.585		
Abdominal pain		0.584		
Pins & needles		0.513		0.317
Eye-soreness		0.489		
Fast/irregular pulse	0.412	0.473		
Headache		0.472	0.397	
Face/lips swelling		0.455		
Dizziness		0.447	0.32	
Blurred vision		0.446		0.343
Nausea		0.44		
Foot sores		0.425		
Head pressure		0.413	0.374	
Itchy welts		0.296		
Diarrhea		0.291		
Weight loss			0.684	
Loss of appetite			0.637	
Drowsiness			0.557	

Speech difficulty		0.554	0.316
Confusion		0.553	
Depression	0.423	0.46	
Difficulty sleeping		0.418	
Anxiety	0.375	0.389	
Delirium			0.741
Disorientation			0.737
Hallucinations			0.696
Visual disturbances			0.51
Altered consciousness			0.446